


Accelerating End to End Development of Large Molecules & Biosimilars

Veeda Group Overview


Veeda Clinical Research Limited ("Veeda") together with its subsidiary, Bioneeds India Private Limited ("Bioneeds"), and its joint venture, Ingenuity BioSciences Private Limited ("Ingenuity"), (together referred to as the "Veeda Group") offers a comprehensive portfolio of clinical, preclinical and bio/analytical services to support innovator, biosimilar and generic drug development programs of our global clientele. We are an independent, institutional investors owned, Board governed and professionally managed contract research group offering scientific leadership, global quality management systems and long term operational and financial stability through a continuing investment in our people, processes, systems, infrastructure and technology and a deep commitment to quality.

Together, we serve clients globally in the following industries



The group entities offers distinct services, both as independent modules as well as integrated services

Assisting you the right way in your entire Drug Development Journey





Quality driven, responsive partner with deep scientific and regulatory expertise in the area of Large Molecule Bioanalysis (including Vaccine)

Ingenuity BioSciences is a joint venture formed by Veeda Clinical Research and Somru BioScience, combining the best of each parent organizations clinical trials and laboratory services capabilities



Our Services and Capabilities



PK

- Biosimilar
- Biologics
- Cell and Gene Therapy



Immunogenicity

- ELISA
- Cell-based Nab
- ELISpot



Biomarker

- Gene Expression
- Protein Expression
- Cellular Profiling
- Cell-based Functional

Multidimensional understanding of the disease biology



Disease etiology/ pathogenesis



Unbiased clinical outcome

Advanced Analysis of Biosimilars with Proven Expertise

In-depth **Expertise**

 Approximately 122 validated methods supporting
 70 biosimilar/bio-better molecules

 US FDA, EMA and Health Canada Global Regulatory Landscape Experience


Key Milestones - 2022

- New Laboratory with Cell-based Assay Capabilities
- Implementation of MSD platform
- Automation

Cell and Gene Therapy

Immunology Assays Cellular/ Functional Assays **Molecular Biology Assays** Flow Cytometry **qPCR ELISA**/ Amplatto™ **MSD** Cell Based Assays **ELISpot** Anti Drug Cytokine Neutralizing CAR expression CD4 and CD8 Pharmacokinetic Antibodies (ADA) antibody assays on cell surface specific T-cell release Biodistribution and shedding viral and transgene responses assay Vector and transgene Quantitation of Protein expression CAR positive PD biomarker measurement T-cells

Innovative Technologies to Support Bioanalysis





mAbY™

- Recombinant antibody discovery platform
- Discover rare and novel antibodies
- Faster discovery
- High-throughput repertoire mining
- Rational antibody design

Amplatto™ - Ultrasensitive Immuno-PCR platform

 Combines traditional immunoPCR workflow with proprietary nanoparticle technology to enable the detection of analyte with unparalleled sensitivity and accuracy






Intelli.b™ - Biosimilar Characterization Solutions

- Platform based on more than 1000 antibodies generated against various innovator drugs
- The antibodies bind to innovator and biosimilar products in an ELISA based system to generate "meaningful finger-print-like analysis"
- This fingerprint is supported by an intelligent library to generate meaningful and actionable interpretation

Cutting edge cloud-based Aegyris[™] that can save up to 70% of time and costs in method validation support activities





Our Infrastructure Capabilities

Equipment and **Software**

- Microplate reader
- Microplate washer
- BOD incubator
- Deep Freezer (-20°C ± 5°C)
- Refrigerator
- AegyrisTM

Critical Instruments and Monitoring

- BD FACSLyric Flow cytometer
- Shimadzu Nexera UHPLC and HPLC
- Q Exactive Orbitrap Mass
- Spectrometer -LC-MS/MS
- ICP-MS
- 2D Electrophoresis- BioRad
- Plate Readers Softmax Pro and Biotek
- Real time PCR- Thermo Fisher
- Bioreactors (5 lts)
- Ekta Purification system
- Gas ChromatographyStability Chambers

LC MS Capabilities

- Q Exactive Orbitrap Mass Spectrometer
- UHPLC Front End
- Software components
 - Xcalibur 4.0.27.19 (Thermo Fisher Scientific Inc.)
 - Biopharma Finder 2.0 Data Analysis Software



Simplifying Immunogenicity Assessment of Biotherapeutic Products - Validated PK & ADA Methods List

PK METHODS

Abatacept (Orencia®)

Abciximab (Reopro®)

Adalimumab (Humira®)

Aflibercept (Eylea®)

Alemtuzumab (Campath®)

Basiliximab (Sumulect®)

Bevacizumab (Avastin®)

C1-inhibitor (Berinert®)

Certolizumab pegol (Cimzia®)

Cetuximab (Erbitux®)

Copaxone

Daclizumab (Zenpax®)

Darbepoetin Alpha

Denosumab

Eculizumab(Soliris®)

Efalizumab (Raptiva®)

Erythropoietin (Epogen®)

Etanercept (Enbrel®)

Etanercept (Enbrel®) FREE

Exendin-4 (Exenatide®)

Factor VIII

Filgrastim (Neupogen®)

Folicle Stimulating Hormone

Gemtuzumab ozogamicin

(Mylotarg®)

Glargine (Lantus®)

Glargine (Lantus®) solution phase

Glucagon (GlucaGen®)

Growth Hormone Releasing

Hepatitis B Immune Globulin

(HepaGam B®)

Hormone (Sermorelin®)

Human Insulin

Ibritumomab tiuxetan (Zevalin®)

IGF-1 (Increlex®)

Imiglucerase (Cerezyme®)

Infliximab (Remicade®)

Insulin Aspart (Novolog®)

Interferon beta-1a

Ipilimumab (Yervoy®)

mPEG

Muromonab-CD3 (Orthoclone OKT3)

Nivolumab (Opdivo®)

Obinutuzumab (GAZYVA®)

Octreotide

Ofatumumab (Arzerra®,

HuMax-CD20)

Omalizumab (Xolair®)

Palivizumab (Synagis®)

Panitumumab(Vectibix®)

Pegfilgrastim (Neulasta®)

Pegylated Proteins

Pembrolizumab (Keytruda®)

Pertuzumab (Perjeta®)

PTH (1-34) - Teriparatide

Ranibizumab(Lucentis®)

Recombinant Human Hyaluronidase

(rhuPH20®)

Rituximab (Rituxan®)

Sargramostim (Leukine®)

Secukinumab (Cosentyx)

Tositumomab (Bexxar®)

Trastuzumab (Herceptin®)

Vedolizumab (Entyvio®)

ADA METHODS

Abatacept (Orencia®)

Abciximab (Reopro®)

Adalimumab (Humira®)

Aflibercept (Eylea®)

Alemtuzumab (Campath®)

Alpha1-Antitrypsin (Prolastin®)

Basiliximab (Sumulect®)

Bevacizumab (Avastin®)

C1-inhibitor (Berinert®)

Certolizumab pegol (Cimzia®)

Cetuximab (Erbitux®)

Copaxone

Daclizumab (Zenpax®)

Darbepoetin Alpha

Denosumab (Prolia®)

Eculizumab(Soliris®)

Efalizumab (Raptiva®)

Erythropoietin (Epogen®)

Etanercept (Enbrel®)

Etanercept (Enbrel®)

Exendin-4 (Exenatide®)

Factor VIII

Filgrastim (Neupogen®

Folicle Stimulating Hormone

Gemtuzumab ozogamicin

(Mylotarg®)

Glargine (Lantus®)

Glargine (Lantus®) solution phase

Glucagon (GlucaGen®)

Growth Hormone Releasing

Hepatitis B Immune Globulin

(HepaGam B®)

Hormone (Sermorelin®)

Human Insulin

Ibritumomab tiuxetan (Zevalin®)

IGF-1 (Increlex®)

Imiglucerase (Cerezyme®)

Infliximab (Remicade®)

Insulin Aspart (Novolog®)

Interferon beta-1a (Avonex®/Rebif®)

Ipilimumab (Yervoy®)

mPEG

Muromonab-CD3 (Orthoclone OKT3)

Nivolumab (Opdivo®)

Obinutuzumab (GAZYVA®)

Octreotide

Ofatumumab (Arzerra®,

HuMax-CD20)

Omalizumab (Xolair®)

Palivizumab (Synagis®)

Panitumumab(Vectibix®)

Pegfilgrastim (Neulasta®)

Pegylated Proteins

Pembrolizumab (Keytruda®)

Pertuzumab (Perjeta®)

PTH (1-34) — Teriparatide

Ranibizumab(Lucentis®)

Recombinant Human Hyaluronidase

Rituximab (Rituxan®)

Sargramostim (Leukine®)

Secukinumab (Cosentyx)

Tositumomab (Bexxar®)

Trastuzumab (Herceptin®)

Ustekinumab (Stelara®)

Vedolizumab (Entyvio®)

Charting the course for Early to Late **Phase Clinical Development**

We cater to key therapeutic areas including:





Dermatology



Psychiatry

Respiratory



Gastroenterology

Endocrinology



Ophthalmology









Rheumatology






Gynaecology




Combined Team Experience in Clinical Trials

More than 300 clinical trials that includes



Veeda Group Advantage



Veeda's Vision

In an industry where innovation is increasingly multifaceted and collaborative, we aspire to be the research partner of choice for innovative (bio) pharmaceutical companies worldwide for their critical product development programs.



Partners in creating a healthier tomorrow